GlassScriptPhysician profile
Sandra V Hazra
NPI 1215972195
$236.55
in general payments reported to CMS, 2019-2025
10 companies · $45.38 in 2025
The $45.38 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.11 · 2022: $35.90 · 2023: $22.89 · 2024: $75.27 · 2025: $45.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $143.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $45.38 | 2025 | Pemazyre, Monjuvi, Jakafi |
| Janssen Biotech, INC. | $38.83 | 2021-2024 | Rybrevant |
| Merck Sharp & Dohme LLC | $22.89 | 2023 | Keytruda, Reblozyl |
| Karyopharm Therapeutics INC. | $21.26 | 2022 | |
| Lilly USA, LLC | $20.14 | 2024 | |
| Servier Pharmaceuticals LLC | $19.88 | 2024 | |
| Coherus Oncology, INC. | $19.79 | 2021 | |
| Genmab U.S., INC. | $17.59 | 2024 | Tivdak |
| Aveo Pharmaceuticals, INC. | $16.15 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Hazra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.